Our recent phase 1 and 2 clinical trials show that the MBP peptide tolerization strategy described above is giving positive results as a therapy for multiple sclerosis (Chataway et al., 2018), and a similar protocol using thyrotropin receptor peptides has delivered improvements in patients with Graves’ hyperthyroidism (Pearce et al., 2019). This evidence concerns the gene TSHR and multiple sclerosis.